One step membrane incorporation of viral antigens as a vaccine candidate against HIV.
Liposomes can been used as potential immunoadjuvants, because they have the ability to elicit both a cellular mediated immune response and a humoral immune response. Studies have shown liposomes to be effective immunopotentiators in hepatitis A and influenza vaccines. For all these purposes, liposomes can be prepared by different methods. After disperging suitable membrane lipids in an aqueous phase and spontaneous formation of multilamellar large vesicles (MLV), mechanical procedures such as ultrasonication, homogenization by a French press or by other high pressure devices and, or extrusion through polycarbonate membranes with defined pore sizes lead to a reduction in size and number of lamellae of the vesicles. A second group of preparation procedures uses suitable detergents, e.g., bile salts or alkylglycosides. A third group of procedures starts with dissolving the lipids in an organic solvent and mixing it with an aqueous phase. The concentration of the organic solvent is then reduced by suitable procedures. Here we present a new technique for the preparation of liposomes with associated membrane proteins, where lipid vesicles are formed immediately after injection into a micellar protein solution. The model membrane protein used for these studies is a truncated recombinant gp41 produced in E. coli. This viral membrane antigen is a possible candidate protein for the establishment of HIV-vaccines. The data presented here, show an efficient and reproducible one step membrane protein encapsulation procedure into liposomes in a closed and sterile containment. We examined encapsulation efficiency, membrane protein conformation and immunogenicity of this possible liposomal vaccine candidate, which can be produced in GMP-compliant quality with the described technique.
Wagner
Andreas
A
Polymun Scientific, Immunbiologische Forschung GmbH, Vienna, Austria. Andreas.Wagner@boku.ac.at
Stiegler
Gabriela
G
Vorauer-Uhl
Karola
K
Katinger
Hermann
H
Quendler
Heribert
H
Hinz
Andreas
A
Weissenhorn
Winfried
W
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D005260:Female; D015488:HIV Antigens / Q000276:immunology*; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C
D016915:AIDS Vaccines; D015488:HIV Antigens